Molbio plans global rollout after four-to-five-month clearance
Key highlights
- Molbio expects its first CDSCO licence for three platforms in about four to five months.
- Molbio plans a global launch that starts in India and faster-approval export markets.
- Molbio has about 1,200 Truenat devices placed in the private sector for potential Trueamp access.
- Management expects six additional veterinary assays to reach the market in fiscal 2028.
powered by IRIS

In its Q2 fiscal 2027 earnings call, Molbio Diagnostics said it expects the first regulatory process for three in-house diagnostic platforms to take about four to five months, after which Molbio plans a global launch beginning in India and selected faster-clearance export markets. The platforms are Trueamp, Truepoc and Truecyte.
Know Molbio Diagnostics inside out
Results, valuation, peers and who's buying, in one view.
When will Molbio launch its three new platforms?
Molbio said it expects to complete the first regulatory path, a Central Drugs Standard Control Organisation, or CDSCO, licence for manufacturing and sale, in about four to five months. Studies for that process were already under way when management discussed the plan during its Q2 fiscal 2027 earnings call. The licence would permit Molbio to launch the platforms in India and export them from India.
The timetable is an expectation rather than a completed approval. Management said market entry will start in India and a few countries where regulatory processes are faster, while registrations in other markets continue. It described the approach as a global launch, not a sequential India-only release, with commercial expansion expected to build over two to three years as country-level approvals are obtained.
What are Trueamp, Truepoc and Truecyte designed to do?
Molbio is positioning Trueamp as a multiplex syndromic testing platform, Truepoc as a screening platform for public-health use, and Truecyte as a near-patient blood-testing platform intended for doctors' offices. The three platforms broaden the product set beyond Truenat, which management described as an existing multi-disease molecular diagnostics platform rather than solely a tuberculosis product.
Trueamp's initial menu is planned to cover respiratory conditions, sexually transmitted infections, human papillomavirus, or HPV, genotyping, sepsis, and antimicrobial resistance. Management said it intends to keep adding panels to Trueamp over time, in the same way it has added diseases to Truenat. It did not disclose a test price, technical comparison or launch sequence for those initial Trueamp panels.
Truecyte is designed to provide cell morphology and cell-count information from a small finger-prick blood sample at a doctor's office. Management said physicians currently may wait one day for such a report, whereas the intended workflow would provide a result while the patient is visiting the doctor. It also said Truecyte is expected to have human and veterinary applications, and veterinary studies had begun with what it described as promising early results.
Truepoc was developed with Gates Foundation support and is intended initially for the public-health screening channel. Chandrasekhar Nair said the foundation's support does not create royalty obligations. The company did not identify the screening diseases, pricing, sales volumes or timing of specific Truepoc programmes in the call.
How will Molbio sell each new diagnostic platform?
Molbio plans to use a different commercial route for each platform, with Trueamp directed largely at private-sector laboratories, Truepoc initially sold through public health, and Truecyte potentially supported by pharmaceutical-company tie-ups. Management said this channel separation reflects the products' differing applications rather than a single distribution model.
For Trueamp, Molbio said it already has about 1,200 Truenat devices placed in the private sector, primarily among standalone laboratories rather than large chains. It has also carved out a private-sector group within its business-development team to promote the platform. Management therefore indicated that existing market connections, supplemented by that specialist team, would be the initial route to customers.
Truepoc is expected to use Molbio's existing global public-health team. Truecyte, by contrast, is meant for the doctor's table and sits between business-to-business and business-to-consumer distribution, according to management. The company said it could consider tie-ups with pharmaceutical companies for Truecyte, but it did not name potential partners, commercial terms or a timetable for such arrangements.
Got a follow-up? Ask IRIS
Are the platforms developed in-house and subject to royalties?
Molbio said all three platforms were developed completely in-house, with no external agencies involved and no royalty payments attached to their commercialisation. That statement applies specifically to Trueamp, Truepoc and Truecyte, not necessarily to every development programme in the company's portfolio.
Management acknowledged that some other ongoing projects may involve future royalty payments, but said those projects are separate from the three planned launches. It also distinguished Gates Foundation support for Truepoc from a licensing arrangement, stating directly that no royalty is payable to the foundation.
On Trueamp, management compared its objective with BioFire, a United States company it identified as offering multiplex testing through a different approach. Molbio did not provide technical specifications, costs or comparative performance data. It said only that Trueamp was designed around affordability requirements in India and other developing-country markets, and declined to elaborate on the technology comparison.
How does the rollout fit Molbio's wider diagnostics strategy?
Molbio said the three launches form part of a plan to operate across molecular diagnostics, radiology and digital pathology, serving both human and veterinary verticals. Management said tuberculosis remains the largest current public-health driver because it is a high-burden infectious disease globally, but maintained that Truenat already addresses multiple diseases.
The company also highlighted planned additions around hepatitis, HPV assays and human immunodeficiency virus, or HIV, viral-load testing on the infectious-disease side. In veterinary diagnostics, one rabies assay is already in the market, while assays for two additional diseases were in development and testing. Management expects the other six veterinary offerings, including the work already under way, to reach the market in fiscal 2028, initially focused on companion-animal conditions such as parvo, canine distemper and leptospirosis.
Management's stated Q2 fiscal 2027 outlook was for 25% top-line growth in the current fiscal year and an earnings before interest, tax, depreciation and amortisation, or EBITDA, margin of about 24% to 25%. Those targets cover the broader business and are not platform-specific forecasts. The call did not quantify how much revenue Trueamp, Truepoc or Truecyte could generate during their first two to three years of rollout.
Conclusion
The disclosed plan is a product and channel expansion: Trueamp would enter private laboratories with syndromic panels, Truepoc would initially target public-health screening, and Truecyte would seek use at the doctor's office. All three are in-house platforms without disclosed royalty payments, and management expects a CDSCO manufacturing-and-sale licence in roughly four to five months.
The next point to watch is whether the stated regulatory process concludes on that timetable, allowing the intended India launch and exports to faster-approval countries. Investors can also monitor which Trueamp panels are introduced first, whether Truecyte partnership discussions result in agreements, and how rapidly registrations extend the rollout over the two-to-three-year period management described.


